Hutchens & Kramer Investment Management Group LLC Purchases 1,110 Shares of Eli Lilly and Company $LLY

Key Points

• Hutchens & Kramer Investment Management Group increased its Eli Lilly stake by 24.4% in the second quarter, purchasing 1,110 additional shares. Its 5,658 shares were valued at approximately $6.8 million, while institutional investors collectively own 82.53% of LLY.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and average price target of $1,292.18. Recent quarterly results exceeded expectations, as Lilly reported $8.38 in EPS and $22.97 billion in revenue, up 47.7% year over year.
• Several Lilly insiders sold shares under pre-arranged Rule 10b5-1 plans, including two executives who sold a combined 8,500 shares; insiders sold 13,500 shares worth nearly $16 million during the last quarter. Investors also continue to weigh the company’s GLP-1 growth against rising competition and future patent-expiration risks.

Hutchens & Kramer Investment Management Group LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 24.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,658 shares of the company's stock after purchasing an additional 1,110 shares during the quarter. Eli Lilly and Company makes up approximately 1.9% of Hutchens & Kramer Investment Management Group LLC's holdings, making the stock its 13th biggest position. Hutchens & Kramer Investment Management Group LLC's holdings in Eli Lilly and Company were worth $6,787,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Coastal Bridge Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $2,959,000. Mosaic Family Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock worth $4,144,000 after buying an additional 1,430 shares during the period. Generali Investments Management Co LLC increased its stake in Eli Lilly and Company by 17.5% in the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock worth $12,258,000 after buying an additional 1,521 shares in the last quarter. Moran Wealth Management LLC raised its holdings in Eli Lilly and Company by 85.6% during the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock valued at $25,072,000 after acquiring an additional 9,638 shares during the period. Finally, Amundi raised its holdings in Eli Lilly and Company by 9.9% during the first quarter. Amundi now owns 5,055,025 shares of the company's stock valued at $4,649,464,000 after acquiring an additional 454,549 shares during the period. Institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In other news, CAO Donald Zakrowski sold 2,000 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last quarter. 0.14% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LLY has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Wolfe Research reissued an "outperform" rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday, May 21st. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a report on Friday, August 7th. The Goldman Sachs Group restated a "buy" rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Royal Bank Of Canada increased their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $1,292.18.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA’s approval of Mounjaro to reduce the risk of heart attack or stroke in certain adults with type 2 diabetes could expand the drug’s addressable market and support Lilly’s next phase of growth. Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
• Positive Sentiment: Analyst sentiment remains favorable, with Lilly’s average brokerage recommendation signaling optimism about its growth outlook, although such ratings can be biased toward positive recommendations. Wall Street Bulls Look Optimistic About Lilly
• Positive Sentiment: Lilly is expanding its neuroscience pipeline through internal development and acquisitions, offering potential long-term growth beyond its diabetes and obesity franchise. Lilly Builds Neuroscience into a New Long-Term Growth Driver
• Positive Sentiment: Recent acquisitions could strengthen Lilly’s pipeline and diversify its future revenue base, though investors are assessing whether the deals will justify their cost. Eli Lilly Has Been on an Acquisition Spree
• Neutral Sentiment: Lilly’s strong GLP-1 growth remains the central investment thesis, but investors are also focused on increasing competition and the eventual impact of patent expirations for Mounjaro, Zepbound and related products. Lilly’s Acquisition Strategy and GLP-1 Competition
• Negative Sentiment: Novartis’ failure in a closely watched cardiovascular trial for an Lp(a)-lowering cholesterol drug pressured the broader drug class and raised concerns about clinical and commercial risk for companies pursuing similar opportunities, including Lilly. Eli Lilly Stock Falls on Novartis Cholesterol Drug Setback
• Negative Sentiment: The stock faced broader healthcare-sector selling and a technical breakdown, which intensified the pullback despite Lilly’s favorable long-term fundamentals. Why Is Eli Lilly Stock Falling Tuesday?
• Negative Sentiment: Novo Nordisk’s positive pediatric semaglutide study highlights continued competitive progress in obesity treatment, potentially increasing pressure on Lilly’s GLP-1 franchise. Novo Nordisk’s Semaglutide Meets Goal in Pediatric Obesity Study

Eli Lilly and Company Stock Down 2.2%

LLY opened at $1,123.60 on Wednesday. The company has a market capitalization of $1.06 trillion, a PE ratio of 37.70, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The firm has a 50-day simple moving average of $1,188.61 and a two-hundred day simple moving average of $1,071.38. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52 week low of $712.05 and a 52 week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's payout ratio is presently 23.22%.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.